BIOPHARMA
By
How AbbVie Is Expanding Its Psychiatry Pipeline Through $1.2B Acquisition of Gilgamesh Pharmaceuticals’s Next-Gen Depression Drug?
Key Highlights The Promise of BretisilocinBretisilocin (GM-2505) is a novel, short-acting 5-HT2A receptor agonist and 5-HT releaser designed…
Can Novartis’ 19 New Cardiovascular Studies at ESC 2025 Redefine the Future of Heart Disease Treatment?
Key Insights Leqvio: Can Inclisiran’s Expanding Role Become a Game-Changer in Cholesterol Management?Novartis is spotlighting the VICTORION-Difference study,…
Could Eli Lilly’s $1.3 Billion GPCR Deal with Superluminal Medicines Unlock a New Era in Targeted Therapeutics?
Key Highlights Eli Lilly Taps AI-Powered Drug Discovery in Landmark GPCR Agreement Eli Lilly has entered a global…
How Will Bayer’s $1.3 Billion Bet on KRAS G12D and Novartis’ Triple Phase 3 Wins Transform Cancer and Immune Therapy?
Key Highlights Bayer Targets KRAS G12D Mutation with Landmark Licensing Deal Bayer has entered a global exclusive licensing…
Is Novartis’ $1.4 Billion Acquisition of Tourmaline Bio a Game-Changer for Cardiovascular Inflammation Therapies?
Key Highlights A $1.4 Billion Bet on Cardiovascular Innovation Novartis announced its agreement to acquire Tourmaline Bio for…
Could Merck and Daiichi Sankyo’s 48% Response Rate with Ifinatamab Deruxtecan Redefine Treatment for Small Cell Lung Cancer?
Key Highlights Promising Phase 2 Data Signals Breakthrough PotentialResults from the IDeate-Lung01 trial demonstrated compelling clinical activity in…
